HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies
- 29 October 2016
- book chapter
- Published by Springer Nature
- p. 257-285
Abstract
No abstract availableKeywords
This publication has 107 references indexed in Scilit:
- Direct-acting and host-targeting HCV inhibitors: current and future directionsCurrent Opinion in Virology, 2012
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant VariantsAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435Antimicrobial Agents and Chemotherapy, 2010
- Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor–induced signal transduction by cleavage of the T‐cell protein tyrosine phosphatase†Hepatology, 2009
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studiesJournal of Molecular Biology, 1999
- The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanismJournal of Molecular Biology, 1999
- Expression, Purification, and Partial Characterization of HCV RNA PolymeraseBiochemical and Biophysical Research Communications, 1997
- Helicases: amino acid sequence comparisons and structure-function relationshipsCurrent Opinion in Structural Biology, 1993
- The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein PrecursorBiochemical and Biophysical Research Communications, 1993